MiLaboratories
@milaboratories.bsky.social
Creators of MiXCR & Platforma: the leading software for the analysis of NGS data for immune profiling. Posting updates on software releases and new features.
Platforma.bio
Platforma.bio
Antibody discovery is moving fast.
But too many teams are still slowed down by fragmented tools, custom scripts, and bioinformatics bottlenecks.
That’s why we're hosting a virtual masterclass on how leading pharma and biotech teams are accelerating lead selection.
Sign up here: bit.ly/4ajVyVS
But too many teams are still slowed down by fragmented tools, custom scripts, and bioinformatics bottlenecks.
That’s why we're hosting a virtual masterclass on how leading pharma and biotech teams are accelerating lead selection.
Sign up here: bit.ly/4ajVyVS
February 12, 2026 at 3:55 PM
Antibody discovery is moving fast.
But too many teams are still slowed down by fragmented tools, custom scripts, and bioinformatics bottlenecks.
That’s why we're hosting a virtual masterclass on how leading pharma and biotech teams are accelerating lead selection.
Sign up here: bit.ly/4ajVyVS
But too many teams are still slowed down by fragmented tools, custom scripts, and bioinformatics bottlenecks.
That’s why we're hosting a virtual masterclass on how leading pharma and biotech teams are accelerating lead selection.
Sign up here: bit.ly/4ajVyVS
Choosing an Antibody Discovery Platform: A 2026 Landscape Review
We compared the current leaders based on five key criteria:
- End-to-end workflow coverage
- Scientist-first usability
- Functionality and visualizations
- Computational throughput
- Data control + flexibility
bit.ly/3LSJFhP
We compared the current leaders based on five key criteria:
- End-to-end workflow coverage
- Scientist-first usability
- Functionality and visualizations
- Computational throughput
- Data control + flexibility
bit.ly/3LSJFhP
Platforma vs. Geneious vs. PipeBio: How to choose the best antibody discovery platform in 2026
Key considerations and a detailed comparison of the leading antibody discovery platforms
bit.ly
February 5, 2026 at 11:12 AM
Choosing an Antibody Discovery Platform: A 2026 Landscape Review
We compared the current leaders based on five key criteria:
- End-to-end workflow coverage
- Scientist-first usability
- Functionality and visualizations
- Computational throughput
- Data control + flexibility
bit.ly/3LSJFhP
We compared the current leaders based on five key criteria:
- End-to-end workflow coverage
- Scientist-first usability
- Functionality and visualizations
- Computational throughput
- Data control + flexibility
bit.ly/3LSJFhP
The most valuable AI in antibody discovery isn’t “generative.” It’s a filter
Labs don’t need 10,000 novel sequences we can’t make. We need AI to flag those that won't survive
The real ROI? Kill bad clones in silico
Saving weeks of failed experiments > hallucinating a “perfect” binder that crashes
Labs don’t need 10,000 novel sequences we can’t make. We need AI to flag those that won't survive
The real ROI? Kill bad clones in silico
Saving weeks of failed experiments > hallucinating a “perfect” binder that crashes
January 29, 2026 at 1:33 PM
The most valuable AI in antibody discovery isn’t “generative.” It’s a filter
Labs don’t need 10,000 novel sequences we can’t make. We need AI to flag those that won't survive
The real ROI? Kill bad clones in silico
Saving weeks of failed experiments > hallucinating a “perfect” binder that crashes
Labs don’t need 10,000 novel sequences we can’t make. We need AI to flag those that won't survive
The real ROI? Kill bad clones in silico
Saving weeks of failed experiments > hallucinating a “perfect” binder that crashes
The analysis gap is the biggest bottleneck in antibody discovery. Too often, teams must choose between fragmented scripts or opaque black-box tools.
Our app note shows how Platforma enables deep repertoire sequencing, functional clustering, and diversity-first selection to cut redundancy and risk.
Our app note shows how Platforma enables deep repertoire sequencing, functional clustering, and diversity-first selection to cut redundancy and risk.
Streamlining Antibody Discovery: From NGS to Functional Validation
High-Throughput In Vitro Antibody Discovery
blog.platforma.bio
January 21, 2026 at 10:46 AM
The analysis gap is the biggest bottleneck in antibody discovery. Too often, teams must choose between fragmented scripts or opaque black-box tools.
Our app note shows how Platforma enables deep repertoire sequencing, functional clustering, and diversity-first selection to cut redundancy and risk.
Our app note shows how Platforma enables deep repertoire sequencing, functional clustering, and diversity-first selection to cut redundancy and risk.
Excited to host our first webinar of the year!
We're partnering with @miltenyibiotec.bsky.social to feature their new next-generation bulk RNA library preparation solution for TCR α/β profiling with advanced analysis and visualization in Platforma.
Register here: bit.ly/4jFH3Qv
Feb 5th @ 5 PM CET
We're partnering with @miltenyibiotec.bsky.social to feature their new next-generation bulk RNA library preparation solution for TCR α/β profiling with advanced analysis and visualization in Platforma.
Register here: bit.ly/4jFH3Qv
Feb 5th @ 5 PM CET
January 14, 2026 at 10:05 AM
Excited to host our first webinar of the year!
We're partnering with @miltenyibiotec.bsky.social to feature their new next-generation bulk RNA library preparation solution for TCR α/β profiling with advanced analysis and visualization in Platforma.
Register here: bit.ly/4jFH3Qv
Feb 5th @ 5 PM CET
We're partnering with @miltenyibiotec.bsky.social to feature their new next-generation bulk RNA library preparation solution for TCR α/β profiling with advanced analysis and visualization in Platforma.
Register here: bit.ly/4jFH3Qv
Feb 5th @ 5 PM CET
A decade ago, immune repertoire sequencing was niche. Today, it’s population-scale.
From 3.5M TCR/BCR samples on MiXCR, key trends emerge:
• Bulk amplicon remains the workhorse
• Single-cell is growing fastest (>50% YoY)
• Academia customizes; industry standardizes
Full article:
bit.ly/4suV1ZG
From 3.5M TCR/BCR samples on MiXCR, key trends emerge:
• Bulk amplicon remains the workhorse
• Single-cell is growing fastest (>50% YoY)
• Academia customizes; industry standardizes
Full article:
bit.ly/4suV1ZG
The State of Immune Repertoire Analysis: Key TCR/BCR Sequencing Trends Shaping the Next Era
We analyzed metadata from over 3.5 million processed samples from 2024–2025. Here is what the data tells us about the future of immunology.
blog.platforma.bio
January 7, 2026 at 8:43 AM
A decade ago, immune repertoire sequencing was niche. Today, it’s population-scale.
From 3.5M TCR/BCR samples on MiXCR, key trends emerge:
• Bulk amplicon remains the workhorse
• Single-cell is growing fastest (>50% YoY)
• Academia customizes; industry standardizes
Full article:
bit.ly/4suV1ZG
From 3.5M TCR/BCR samples on MiXCR, key trends emerge:
• Bulk amplicon remains the workhorse
• Single-cell is growing fastest (>50% YoY)
• Academia customizes; industry standardizes
Full article:
bit.ly/4suV1ZG
What a year for our global research community 🌍
In 2025, together we:
• Processed 1.5 PB of data (+50% YoY)
• Welcomed 2,400 new users across 375 institutions
• Were cited in 741 publications
• Shipped 30 new biological blocks
On to an even bigger 2026 🚀
In 2025, together we:
• Processed 1.5 PB of data (+50% YoY)
• Welcomed 2,400 new users across 375 institutions
• Were cited in 741 publications
• Shipped 30 new biological blocks
On to an even bigger 2026 🚀
December 18, 2025 at 11:24 AM
What a year for our global research community 🌍
In 2025, together we:
• Processed 1.5 PB of data (+50% YoY)
• Welcomed 2,400 new users across 375 institutions
• Were cited in 741 publications
• Shipped 30 new biological blocks
On to an even bigger 2026 🚀
In 2025, together we:
• Processed 1.5 PB of data (+50% YoY)
• Welcomed 2,400 new users across 375 institutions
• Were cited in 741 publications
• Shipped 30 new biological blocks
On to an even bigger 2026 🚀
What if we’ve been studying TILs wrong?
A new low-intervention study found:
— High-TIL areas had both CD4+ and CD8+ T cells
— Low-TIL areas skewed to CD4+ T cells with fewer cytotoxic markers
— CD4+ T cells had less diverse TCRs
MiXCR identified TILs with the highest therapeutic potential.
A new low-intervention study found:
— High-TIL areas had both CD4+ and CD8+ T cells
— Low-TIL areas skewed to CD4+ T cells with fewer cytotoxic markers
— CD4+ T cells had less diverse TCRs
MiXCR identified TILs with the highest therapeutic potential.
December 15, 2025 at 5:36 PM
What if we’ve been studying TILs wrong?
A new low-intervention study found:
— High-TIL areas had both CD4+ and CD8+ T cells
— Low-TIL areas skewed to CD4+ T cells with fewer cytotoxic markers
— CD4+ T cells had less diverse TCRs
MiXCR identified TILs with the highest therapeutic potential.
A new low-intervention study found:
— High-TIL areas had both CD4+ and CD8+ T cells
— Low-TIL areas skewed to CD4+ T cells with fewer cytotoxic markers
— CD4+ T cells had less diverse TCRs
MiXCR identified TILs with the highest therapeutic potential.
Antibody discovery becomes far more powerful when functional assay data and NGS are brought together.
In Platforma’s antibody space, overlaying immune assay targets with clonotypes makes enriched, functionally validated clones pop instantly, letting teams spot high-value hits faster.
In Platforma’s antibody space, overlaying immune assay targets with clonotypes makes enriched, functionally validated clones pop instantly, letting teams spot high-value hits faster.
December 10, 2025 at 1:59 PM
Antibody discovery becomes far more powerful when functional assay data and NGS are brought together.
In Platforma’s antibody space, overlaying immune assay targets with clonotypes makes enriched, functionally validated clones pop instantly, letting teams spot high-value hits faster.
In Platforma’s antibody space, overlaying immune assay targets with clonotypes makes enriched, functionally validated clones pop instantly, letting teams spot high-value hits faster.
Coupled with other filters for sequence liability and enrichment scores, this decision funnel guarantees a panel of leads that are both enriched and biologically diverse.
Couldn't make it to our webinar? Watch the recording on-demand:
www.youtube.com/watch?v=hhsL...
Couldn't make it to our webinar? Watch the recording on-demand:
www.youtube.com/watch?v=hhsL...
December 9, 2025 at 4:13 PM
Coupled with other filters for sequence liability and enrichment scores, this decision funnel guarantees a panel of leads that are both enriched and biologically diverse.
Couldn't make it to our webinar? Watch the recording on-demand:
www.youtube.com/watch?v=hhsL...
Couldn't make it to our webinar? Watch the recording on-demand:
www.youtube.com/watch?v=hhsL...
Last week during our antibody discovery webinar, we gave a live demo of our lead selection block.
Unlike the common “Top N” approach, which can bias selection toward a single dominant family, we use a Diversity-First algorithm to pick the top representative from each family to ensure diversity.
Unlike the common “Top N” approach, which can bias selection toward a single dominant family, we use a Diversity-First algorithm to pick the top representative from each family to ensure diversity.
December 9, 2025 at 4:12 PM
Last week during our antibody discovery webinar, we gave a live demo of our lead selection block.
Unlike the common “Top N” approach, which can bias selection toward a single dominant family, we use a Diversity-First algorithm to pick the top representative from each family to ensure diversity.
Unlike the common “Top N” approach, which can bias selection toward a single dominant family, we use a Diversity-First algorithm to pick the top representative from each family to ensure diversity.
Last chance to register for our antibody discovery webinar tomorrow at 11 AM EST/ 5 PM CET!
Learn how to:
• Uncover emergent clones & immune responses
• Track enrichment and liabilities
• Predict structure & affinity from sequence
• Find top leads without coding
Sign up here: t.co/3Ye6fj1EAA
Learn how to:
• Uncover emergent clones & immune responses
• Track enrichment and liabilities
• Predict structure & affinity from sequence
• Find top leads without coding
Sign up here: t.co/3Ye6fj1EAA
https://bit.ly/4oVepwJ
t.co
December 2, 2025 at 7:03 AM
Last chance to register for our antibody discovery webinar tomorrow at 11 AM EST/ 5 PM CET!
Learn how to:
• Uncover emergent clones & immune responses
• Track enrichment and liabilities
• Predict structure & affinity from sequence
• Find top leads without coding
Sign up here: t.co/3Ye6fj1EAA
Learn how to:
• Uncover emergent clones & immune responses
• Track enrichment and liabilities
• Predict structure & affinity from sequence
• Find top leads without coding
Sign up here: t.co/3Ye6fj1EAA
Wrapping up our last Platforma Pioneers workshop at @bostonchildrens.bsky.social!
Joining forces with over 40 members of the Harvard network, our team helped spark collaboration and share knowledge, empowering biologists to run their own downstream analyses themselves.
Thank you for hosting us!
Joining forces with over 40 members of the Harvard network, our team helped spark collaboration and share knowledge, empowering biologists to run their own downstream analyses themselves.
Thank you for hosting us!
November 27, 2025 at 4:26 PM
Wrapping up our last Platforma Pioneers workshop at @bostonchildrens.bsky.social!
Joining forces with over 40 members of the Harvard network, our team helped spark collaboration and share knowledge, empowering biologists to run their own downstream analyses themselves.
Thank you for hosting us!
Joining forces with over 40 members of the Harvard network, our team helped spark collaboration and share knowledge, empowering biologists to run their own downstream analyses themselves.
Thank you for hosting us!
Want to learn more about how top teams combine sequence, functional, and structural analysis to prioritize true therapeutic candidates?
Join our webinar next week.
bit.ly/4oY9s69
Join our webinar next week.
bit.ly/4oY9s69
November 25, 2025 at 1:24 PM
Want to learn more about how top teams combine sequence, functional, and structural analysis to prioritize true therapeutic candidates?
Join our webinar next week.
bit.ly/4oY9s69
Join our webinar next week.
bit.ly/4oY9s69
What everyone in antibody discovery should know:
1. How to combine NGS with functional assay data to reveal truly high-potential clones
2. Not all lead candidates are therapeutic candidates
3. Prioritize developability from the start. Spot sequence liabilities early to derisk your pipeline.
1. How to combine NGS with functional assay data to reveal truly high-potential clones
2. Not all lead candidates are therapeutic candidates
3. Prioritize developability from the start. Spot sequence liabilities early to derisk your pipeline.
November 25, 2025 at 1:24 PM
What everyone in antibody discovery should know:
1. How to combine NGS with functional assay data to reveal truly high-potential clones
2. Not all lead candidates are therapeutic candidates
3. Prioritize developability from the start. Spot sequence liabilities early to derisk your pipeline.
1. How to combine NGS with functional assay data to reveal truly high-potential clones
2. Not all lead candidates are therapeutic candidates
3. Prioritize developability from the start. Spot sequence liabilities early to derisk your pipeline.
MiXCR powered BCR extraction in this study, and with Platforma you can now go further—model structure, predict binding affinity, and rank top antibody leads by developability.
Learn more here: platforma.bio/antibody-dis...
#antibody #antibodydiscovery #antibodyengineering
Learn more here: platforma.bio/antibody-dis...
#antibody #antibodydiscovery #antibodyengineering
November 20, 2025 at 12:23 PM
MiXCR powered BCR extraction in this study, and with Platforma you can now go further—model structure, predict binding affinity, and rank top antibody leads by developability.
Learn more here: platforma.bio/antibody-dis...
#antibody #antibodydiscovery #antibodyengineering
Learn more here: platforma.bio/antibody-dis...
#antibody #antibodydiscovery #antibodyengineering
🧬 New deep learning model profiles antigen–antibody interactions at scale!
Cmai predicts antigen–BCR binding from standard RNA-seq with >0.90 AUROC—unlocking biomarker discovery, treatment response prediction, and even forecasting immune-related toxicities up to 120 days before onset.
Cmai predicts antigen–BCR binding from standard RNA-seq with >0.90 AUROC—unlocking biomarker discovery, treatment response prediction, and even forecasting immune-related toxicities up to 120 days before onset.
November 20, 2025 at 12:21 PM
🧬 New deep learning model profiles antigen–antibody interactions at scale!
Cmai predicts antigen–BCR binding from standard RNA-seq with >0.90 AUROC—unlocking biomarker discovery, treatment response prediction, and even forecasting immune-related toxicities up to 120 days before onset.
Cmai predicts antigen–BCR binding from standard RNA-seq with >0.90 AUROC—unlocking biomarker discovery, treatment response prediction, and even forecasting immune-related toxicities up to 120 days before onset.
Platforma Pioneers Tour — UCSD & @lji.org
40 researchers, one clear takeaway: Platforma bridges the gap.
Biologists can analyze data without waiting
Core facilities empower users beyond count matrices
Bioinformaticians can focus on innovation
Platforma doesn't replace expertise, it unlocks it.
40 researchers, one clear takeaway: Platforma bridges the gap.
Biologists can analyze data without waiting
Core facilities empower users beyond count matrices
Bioinformaticians can focus on innovation
Platforma doesn't replace expertise, it unlocks it.
November 19, 2025 at 12:40 PM
Platforma Pioneers Tour — UCSD & @lji.org
40 researchers, one clear takeaway: Platforma bridges the gap.
Biologists can analyze data without waiting
Core facilities empower users beyond count matrices
Bioinformaticians can focus on innovation
Platforma doesn't replace expertise, it unlocks it.
40 researchers, one clear takeaway: Platforma bridges the gap.
Biologists can analyze data without waiting
Core facilities empower users beyond count matrices
Bioinformaticians can focus on innovation
Platforma doesn't replace expertise, it unlocks it.
Want to accelerate your antibody discovery workflow?
Join our webinar to learn how to prioritize lead candidates faster.
You’ll discover how to track enrichment and liabilities, monitor clone dynamics over time, and predict developability to minimize risk
Register here: bit.ly/4p8157W
Join our webinar to learn how to prioritize lead candidates faster.
You’ll discover how to track enrichment and liabilities, monitor clone dynamics over time, and predict developability to minimize risk
Register here: bit.ly/4p8157W
November 13, 2025 at 3:36 PM
Want to accelerate your antibody discovery workflow?
Join our webinar to learn how to prioritize lead candidates faster.
You’ll discover how to track enrichment and liabilities, monitor clone dynamics over time, and predict developability to minimize risk
Register here: bit.ly/4p8157W
Join our webinar to learn how to prioritize lead candidates faster.
You’ll discover how to track enrichment and liabilities, monitor clone dynamics over time, and predict developability to minimize risk
Register here: bit.ly/4p8157W
This week, we kicked off our Platforma Pioneers academic tour at UCLA!
Our hands-on workshop on how to accelerate no-code NGS data analysis with Platforma was a blast.
A big thank you to everyone who joined us—we loved seeing your curiosity and creativity in action!
🚗 Next stops - USC and UCSD!
Our hands-on workshop on how to accelerate no-code NGS data analysis with Platforma was a blast.
A big thank you to everyone who joined us—we loved seeing your curiosity and creativity in action!
🚗 Next stops - USC and UCSD!
November 12, 2025 at 2:46 PM
This week, we kicked off our Platforma Pioneers academic tour at UCLA!
Our hands-on workshop on how to accelerate no-code NGS data analysis with Platforma was a blast.
A big thank you to everyone who joined us—we loved seeing your curiosity and creativity in action!
🚗 Next stops - USC and UCSD!
Our hands-on workshop on how to accelerate no-code NGS data analysis with Platforma was a blast.
A big thank you to everyone who joined us—we loved seeing your curiosity and creativity in action!
🚗 Next stops - USC and UCSD!
RNA-seq to monitor minimal residual disease (MRD) in multiple myeloma?
A recent Nature study found that RNA-seq achieved higher sensitivity and stronger prognostic value than DNA-seq for MRD.
We're proud that MiXCR was the key tool in this study.
Read more here: x.com/MiLaboratori...
A recent Nature study found that RNA-seq achieved higher sensitivity and stronger prognostic value than DNA-seq for MRD.
We're proud that MiXCR was the key tool in this study.
Read more here: x.com/MiLaboratori...
November 6, 2025 at 12:42 PM
RNA-seq to monitor minimal residual disease (MRD) in multiple myeloma?
A recent Nature study found that RNA-seq achieved higher sensitivity and stronger prognostic value than DNA-seq for MRD.
We're proud that MiXCR was the key tool in this study.
Read more here: x.com/MiLaboratori...
A recent Nature study found that RNA-seq achieved higher sensitivity and stronger prognostic value than DNA-seq for MRD.
We're proud that MiXCR was the key tool in this study.
Read more here: x.com/MiLaboratori...
We just wrapped up two impactful days at the Cell Symposium in Sitges, Spain with Cellecta! Was great to be face-to-face with researchers: live demos of Platforma, learning more about what others are working on, and sharing what our teams have been building.
Thanks to everyone who stopped by!
Thanks to everyone who stopped by!
November 5, 2025 at 2:50 PM
We just wrapped up two impactful days at the Cell Symposium in Sitges, Spain with Cellecta! Was great to be face-to-face with researchers: live demos of Platforma, learning more about what others are working on, and sharing what our teams have been building.
Thanks to everyone who stopped by!
Thanks to everyone who stopped by!
Proud to share a new study advancing non-invasive immune monitoring in cancer. Researchers found tumor-derived TCR clonotypes enriched in cfDNA and persisting >50 weeks in circulating T cells.
Proud that MiXCR powered large-scale TCR sequencing across tumor, blood, and cfDNA.
#cfDNA #TCRseq #TCR
Proud that MiXCR powered large-scale TCR sequencing across tumor, blood, and cfDNA.
#cfDNA #TCRseq #TCR
October 30, 2025 at 11:44 AM
Big news: we’ve launched an interactive demo on the Platforma website!
Choose your own scientific adventure:
🔹 Antibody Discovery
🔹 Differential Gene Expression
🔹 Single Cell Multiomics
🔹 TCR/BCR Repertoire Analysis
👉 Dive into the demo here: shorturl.at/7tkD4
#NGS #Multiomics #TCR #BCR
Choose your own scientific adventure:
🔹 Antibody Discovery
🔹 Differential Gene Expression
🔹 Single Cell Multiomics
🔹 TCR/BCR Repertoire Analysis
👉 Dive into the demo here: shorturl.at/7tkD4
#NGS #Multiomics #TCR #BCR
October 28, 2025 at 8:06 AM
Big news: we’ve launched an interactive demo on the Platforma website!
Choose your own scientific adventure:
🔹 Antibody Discovery
🔹 Differential Gene Expression
🔹 Single Cell Multiomics
🔹 TCR/BCR Repertoire Analysis
👉 Dive into the demo here: shorturl.at/7tkD4
#NGS #Multiomics #TCR #BCR
Choose your own scientific adventure:
🔹 Antibody Discovery
🔹 Differential Gene Expression
🔹 Single Cell Multiomics
🔹 TCR/BCR Repertoire Analysis
👉 Dive into the demo here: shorturl.at/7tkD4
#NGS #Multiomics #TCR #BCR
🧬 Join our team: We’re hiring a Scientific Sales Development Representative in Bilbao!
Who you are: Degree in Biology/Bioinformatics (or similar), strong English, 0–2 years’ experience
lnkd.in/dxMXRT84
Who you are: Degree in Biology/Bioinformatics (or similar), strong English, 0–2 years’ experience
lnkd.in/dxMXRT84
MiLaboratories hiring Scientific Sales Development Representative in Bilbao, Basque Country, Spain | LinkedIn
Posted 11:04:05 AM. TL;DR🧬 NGS data analysis platform for biologists🚀 Backed by Speedinvest and K Fund among others —…See this and similar jobs on LinkedIn.
lnkd.in
October 27, 2025 at 6:45 PM
🧬 Join our team: We’re hiring a Scientific Sales Development Representative in Bilbao!
Who you are: Degree in Biology/Bioinformatics (or similar), strong English, 0–2 years’ experience
lnkd.in/dxMXRT84
Who you are: Degree in Biology/Bioinformatics (or similar), strong English, 0–2 years’ experience
lnkd.in/dxMXRT84